Merck expands haematology portfolio with acquisition of Imago for $1.35bn
Oncology
NETRIS Pharma begins subject dosing in solid tumour therapy trial
The trial will assess the biological and clinical activity of NP137 as an add-on therapy in solid tumours patients.
Innovation in immuno-oncology: Leading companies in anti-tumour antibodies
Innovation in immuno-oncology: Leading companies in antibody drug conjugates (ADC) cancer therapy
STORM Therapeutics begins subject dosing in solid tumour therapy trial
University of Manchester opens precision medicine trial for rare cancers
DLBCL: a rapidly evolving treatment landscape with a crowded pipeline
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
